58553-56-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2,6-Naphthyridin-1(2H)-one, 3,4-dihydroserves as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Research and Development:
In the field of research and development, 2,6-Naphthyridin-1(2H)-one, 3,4-dihydrois employed to explore its potential biological activity and therapeutic properties. This can lead to the discovery of new treatments and advancements in medicine.
Used in Drug Discovery:
2,6-Naphthyridin-1(2H)-one, 3,4-dihydrois utilized in drug discovery processes to identify and develop new pharmaceutical agents with improved efficacy and safety profiles. Its unique chemical structure makes it a promising candidate for the creation of innovative therapeutics.

Upstream product

• 58553-55-2 ethyl 3-cyanomethylisonicotinate 
• 1365762-81-7 2-(4-methoxybenzyl)-3,4-dihydro-2,6-naphthyridin-1(2H)-one 
• 1365762-79-3 3-(2-hydroxyethyl)-N-(4-methoxybenzyl)isonicotinamide 
• 4427-20-7 3,4-dihydro-1H-pyrano[4,3-c]pyridin-1-one 
• 1365762-76-0 3-(2-hydroxyethyl)isonicotinonitrile 
• 3423-46-9 ethyl 2-(4-cyanopyridin-3-yl)acetate 
• 1365762-73-7 3-(2-ethoxy-2-oxoethyl)pyridine-1-oxide ethyl iodide 
• 3423-47-0 3-(2-ethoxy-2-oxoethyl)pyridin-1-ium-1-olate 
• 39931-77-6 pyridin-3-yl-acetic acid ethyl ester 

Relevant academic research and scientific papers

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME

Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R1 and R2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R1 and R2, together with a nitrogen atom to which R1 and R2 are attached, may form a ring; R3 and R4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R2 and R3 may be attached to each other to form -(CH2)m-, -N=CH-, -CH=N-, or -(C1-6 alkyl)C=N-; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group -C(=O)N(R5)R6 or group -C(=O)OR7, R8 is absent or represents a bond, an oxygen atom, a sulfur atom, -SO2-, -SO-, -CH2-CH2-, or - CH=CH-, and R9 and R10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents - (CH2)n-, -O-(CH2)i-, or -C(=O)NH-(CH2)i-.